BioSpace News Archive

Nested Therapeutics today presented the first preclinical data from its lead candidate, NST-628, a mechanistically novel non-degrading molecular glue that targets multiple nodes in the RAS/MAPK pathway, outlined in three poster presentations at the 2023 AACR-NCI-EORTC International Conference taking place in Boston, Massachusetts from October 11-15, 2023.

SK Biopharmaceuticals and Proteovant Therapeutics, presented data showing that selectively degrading the epigenetic protein p300, with minimal impact on its paralog CBP, results in suppression of androgen receptor signaling and inhibition of tumor growth in a mouse model of androgen receptor (AR) positive prostate cancer.

Sight Sciences, Inc. announced the presentation of the full phase I results from the SAHARA randomized controlled trial.

Xtant Medical Holdings, Inc. announced it will exhibit its suite of orthobiologics and spinal fixation products at the North American Spine Society 2023 Annual Meeting, which will be held October 18-21 at the Los Angeles Convention Center in Los Angeles, CA.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Vir’s Executive Vice President, Chief Medical Officer and Interim Head of Research, is participating in a virtual fireside Q&A at the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference on Wednesday, October 25, at 7:00 a.m. PT / 10:00 a.m. ET.

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today reported financial results for the fiscal quarter ended August 31, 2023, and provided a corporate update.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”) today provided an update on its Phase 3 open-label registrational clinical trial (the REGAL study) for galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML) who have achieved complete remission following second-line salvage therapy (CR2 patients).

PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2023 financial results on Monday, October 30, 2023, at 4:30 pm Eastern Time.

Foundation Medicine Inc. announced that it has received approval from the U.S. Food and Drug Administration for FoundationOne®CDx and FoundationOne®Liquid CDx to be used as companion diagnostics for Pfizer’s BRAFTOVI® in combination with MEKTOVI® for the treatment of adult patients with metastatic non-small cell lung cancer with a BRAF V600E mutation.

On September 27, 2023, HealthPlan Data Solutions (HDS) executives presented initial results from its pharmacy payment integrity program implemented with the Kentucky Employees’ Health Plan (KEHP) during an Interim Joint Committee meeting on Health Services.